• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

胰腺癌的进化树

The Evolutionary Forest of Pancreatic Cancer.

作者信息

Mullen Katelyn M, Hong Jungeui, Attiyeh Marc A, Hayashi Akimasa, Sakamoto Hitomi, Kohutek Zachary A, McIntyre Caitlin A, Zhang Haochen, Makohon-Moore Alvin P, Zucker Amanda, Wood Laura D, Myers Matthew A, Arnold Brian J, Zaccaria Simone, Chou Joanne F, Capanu Marinela, Socci Nicholas D, Raphael Benjamin J, Iacobuzio-Donahue Christine A

机构信息

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.

Division of Gastrointestinal Pathology, Department of Pathology, Johns Hopkins Hospital, Baltimore, Maryland.

出版信息

Cancer Discov. 2025 Feb 7;15(2):329-345. doi: 10.1158/2159-8290.CD-23-1541.

DOI:10.1158/2159-8290.CD-23-1541
PMID:39378050
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11803399/
Abstract

Although the pancreatic cancer genome has been described, it has not been explored with respect to stages of diagnosis or treatment bottlenecks. We now describe and quantify the genomic features of PDAC in the context of evolutionary metrics and in doing so have identified a novel prognostic biomarker.

摘要

尽管胰腺癌基因组已被描述，但尚未从诊断阶段或治疗瓶颈方面进行探索。我们现在在进化指标的背景下描述并量化了胰腺导管腺癌（PDAC）的基因组特征，在此过程中识别出了一种新的预后生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78af/11803399/f72f6a00f44f/cd-23-1541fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78af/11803399/4102fc139170/cd-23-1541fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78af/11803399/482af80713f1/cd-23-1541fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78af/11803399/9eb1aac1397c/cd-23-1541fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78af/11803399/c3e65361e010/cd-23-1541fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78af/11803399/831693d0f88f/cd-23-1541fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78af/11803399/289352c52c58/cd-23-1541fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78af/11803399/f72f6a00f44f/cd-23-1541fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78af/11803399/4102fc139170/cd-23-1541fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78af/11803399/482af80713f1/cd-23-1541fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78af/11803399/9eb1aac1397c/cd-23-1541fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78af/11803399/c3e65361e010/cd-23-1541fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78af/11803399/831693d0f88f/cd-23-1541fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78af/11803399/289352c52c58/cd-23-1541fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78af/11803399/f72f6a00f44f/cd-23-1541fig7.jpg

相似文献

1
The Evolutionary Forest of Pancreatic Cancer.胰腺癌的进化树
Cancer Discov. 2025 Feb 7;15(2):329-345. doi: 10.1158/2159-8290.CD-23-1541.
2
PLAGL2 as a prognostic biomarker and an EMT-promoting factor in PDAC.PLAGL2作为胰腺癌的一种预后生物标志物和上皮-间质转化促进因子。
Sci Rep. 2025 Jul 14;15(1):25425. doi: 10.1038/s41598-025-09591-x.
3
microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis.具有胰腺导管腺癌预后意义的 microRNAs：一项荟萃分析。
Eur J Cancer. 2015 Jul;51(11):1389-404. doi: 10.1016/j.ejca.2015.04.006. Epub 2015 May 19.
4
Gene Methylation in Tumors with Low CD8 T-Cell Infiltration Drives Positive Prognostic Overall Survival Responses in Pancreatic Ductal Adenocarcinoma.低CD8 T细胞浸润肿瘤中的基因甲基化驱动胰腺导管腺癌的总体生存预后良好。
Int J Mol Sci. 2025 Jun 10;26(12):5567. doi: 10.3390/ijms26125567.
5
Attenuated immune surveillance during squamous cell transformation of pancreatic adenosquamous cancer defines new therapeutic opportunity for cancer interception.胰腺腺鳞癌鳞状细胞转化过程中免疫监视功能减弱为癌症拦截提供了新的治疗机会。
J Immunother Cancer. 2025 Jun 23;13(6):e012066. doi: 10.1136/jitc-2025-012066.
6
Prognostic value of cancer stem cell marker CD133 expression in pancreatic ductal adenocarcinoma (PDAC): a systematic review and meta-analysis.癌症干细胞标志物CD133表达在胰腺导管腺癌（PDAC）中的预后价值：一项系统评价和荟萃分析
Int J Clin Exp Pathol. 2015 Oct 1;8(10):12084-92. eCollection 2015.
7
Spatial Transcriptomics Reveals Cancer and Stromal Cell Heterogeneity Between Center and Invasive Front of Pancreatic Cancer.空间转录组学揭示胰腺癌中心与侵袭前沿之间的癌症和基质细胞异质性。
Mod Pathol. 2025 Jun;38(6):100726. doi: 10.1016/j.modpat.2025.100726. Epub 2025 Jan 29.
8
A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial.一项用于胰腺癌个性化治疗的整合基因组学与化身模型的III期随机试验：AVATAR试验。
Clin Cancer Res. 2025 Jan 17;31(2):278-287. doi: 10.1158/1078-0432.CCR-23-4026.
9
Redefining phenotypic intratumor heterogeneity of pancreatic ductal adenocarcinoma: a bottom-up approach.重新定义胰腺导管腺癌的肿瘤内表型异质性：一种自下而上的方法。
J Pathol. 2025 Apr;265(4):448-461. doi: 10.1002/path.6398. Epub 2025 Feb 11.
10
Clinicopathological significance of SMAD4 loss in pancreatic ductal adenocarcinomas: a systematic review and meta-analysis.SMAD4缺失在胰腺导管腺癌中的临床病理意义：一项系统评价和荟萃分析
Oncotarget. 2017 Mar 7;8(10):16704-16711. doi: 10.18632/oncotarget.14335.

引用本文的文献

1
KRAS: the Achilles' heel of pancreas cancer biology.KRAS：胰腺癌生物学的致命弱点。
J Clin Invest. 2025 Aug 15;135(16). doi: 10.1172/JCI191939.
2
Oligometastatic pancreatic cancer: current state of management and emerging therapies.寡转移胰腺癌：治疗现状与新兴疗法
Oncologist. 2025 Jun 4;30(6). doi: 10.1093/oncolo/oyaf154.
3
GABRP Mediates GABA-A Receptor to Shape Tumor Immunosuppressive Microenvironment and Promote Tumor Immune Escape and Corresponding Targeted Therapy.GABRP介导GABA-A受体塑造肿瘤免疫抑制微环境并促进肿瘤免疫逃逸及相应的靶向治疗。

本文引用的文献

1
HATCHet2: clone- and haplotype-specific copy number inference from bulk tumor sequencing data.HATCHet2：基于批量肿瘤测序数据的克隆和单体型特异性拷贝数推断。
Genome Biol. 2024 May 21;25(1):130. doi: 10.1186/s13059-024-03267-x.
2
Pan-cancer whole-genome comparison of primary and metastatic solid tumours.泛癌种原发性和转移性实体瘤全基因组比较
Nature. 2023 Jun;618(7964):333-341. doi: 10.1038/s41586-023-06054-z. Epub 2023 May 10.
3
The evolution of lung cancer and impact of subclonal selection in TRACERx.肺癌的演变及 TRACERx 中亚克隆选择的影响。
Cancer Med. 2025 Jun;14(11):e70946. doi: 10.1002/cam4.70946.
Nature. 2023 Apr;616(7957):525-533. doi: 10.1038/s41586-023-05783-5. Epub 2023 Apr 12.
4
Anti-tumor efficacy of a potent and selective non-covalent KRAS inhibitor.一种强效且选择性的非共价 KRAS 抑制剂的抗肿瘤功效。
Nat Med. 2022 Oct;28(10):2171-2182. doi: 10.1038/s41591-022-02007-7. Epub 2022 Oct 10.
5
Neoantigen quality predicts immunoediting in survivors of pancreatic cancer.新抗原质量可预测胰腺癌幸存者的免疫编辑。
Nature. 2022 Jun;606(7913):389-395. doi: 10.1038/s41586-022-04735-9. Epub 2022 May 19.
6
Intratumor heterogeneity reflects clinical disease course.肿瘤内异质性反映临床病程。
Nat Cancer. 2020 Jan;1(1):3-6. doi: 10.1038/s43018-019-0002-1.
7
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.25000 例患者前瞻性临床测序的转移模式的基因组特征分析。
Cell. 2022 Feb 3;185(3):563-575.e11. doi: 10.1016/j.cell.2022.01.003.
8
A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma.转录异质性和胰腺导管腺癌鳞状特征的统一范式。
Nat Cancer. 2020 Jan;1(1):59-74. doi: 10.1038/s43018-019-0010-1. Epub 2020 Jan 13.
9
Primary and metastatic peritoneal surface malignancies.原发性和转移性腹膜表面恶性肿瘤。
Nat Rev Dis Primers. 2021 Dec 16;7(1):91. doi: 10.1038/s41572-021-00326-6.
10
Preoperative predictors for early and very early disease recurrence in patients undergoing resection of pancreatic ductal adenocarcinoma.术前预测因素可用于评估接受胰腺导管腺癌切除术患者的早期和极早期疾病复发。
HPB (Oxford). 2022 Apr;24(4):535-546. doi: 10.1016/j.hpb.2021.09.004. Epub 2021 Sep 24.